Версия сайта для людей с нарушением зрения
    шрифт
только для медицинских специалистов

Консультант врача

Электронная медицинская библиотека

Обычная версия
Раздел 30 / 31
Страница 1 / 1

СПИСОК ЛИТЕРАТУРЫ

  1. Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C. et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC // Eur. Heart J. 2021. Vol. 42 (5). P. 373–498. DOI: 10.1093/eurheartj/ehaa612.
  2. Steffel J., Collins R., Antz M., Cornu P., Desteghe L., Haeusler K.G. et al. External reviewers. 2021 European heart rhythm association practical guide on the use of non-vitamin K Antagonist oral anticoagulants in patients with atrial fibrillation // Europace. 2021. Vol 23 (10). P. 1612–1676. DOI: 10.1093/europace/euab065.
  3. Pisters R., Lane D.A., Marin F., Camm A.J., Lip G.Y. Stroke and throm­boembolism in atrial fibrillation // Circ J. 2012. Vol. 76 (10). P. 2289–304. DOI: 10.1253/circj.cj-12–1036.
  4. Ganesan A.N., Chew D.P., Hartshorne T., Selvanayagam J.B., Aylward P.E., Sanders P. et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis // Eur. Heart J. 2016. Vol. 37 (20). P. 1591–602. DOI: 10.1093/eurheartj/ehw007.
  5. Rutherford O.W., Jonasson C., Ghanima W., Holst R., Halvorsen S. New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs // Open Heart. 2018. Vol. 5 (2). P. e000931. DOI: 10.1136/openhrt-2018–000931. Erratum in: Open Heart. 2020. Vol. 7(1). P. e000931corr1.
  6. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease // Kidney Int. 2020. Vol. 98 (4S). P. S1–S115. DOI: 10.1016/j.kint.2020.06.019.
  7. Levin A., Stevens P.E. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward // Kidney Int. 2014. Vol. 85 (1). P. 49–61. DOI: 10.1038/ki.2013.444.
  8. Okumura K., Akao M., Yoshida T., Kawata M., Okazaki O., Akashi S et al. ELDERCARE-AF Committees and Investigators. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation // N. Engl. J. Med. 2020. Vol. 383 (18). P. 1735–1745. DOI: 10.1056/NEJMoa2012883.
  9. Tiedemann A., Lord S.R., Sherrington C. The development and validation of a brief performance-based fall risk assessment tool for use in primary care // J Gerontol A Biol Sci Med Sci. 2010. Vol. 65 (8). P. 896–903. DOI: 10.1093/gerona/glq067.
  10. Janion-Sadowska A., Papuga-Szela E., Łukaszuk R., Chrapek M., Undas A. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia // J. Cardiovasc. Pharmacol. 2018. Vol. 72 (3). P. 153–160. DOI: 10.1097/FJC.0000000000000607.
  11. Malik A.H., Yandrapalli S., Shetty S., Aronow W.S., Jain D., Frishman W.H. et al. MAGIC (Meta-analysis And oriGinal Investigations in Cardiology) Investigators // Impact of weight on the efficacy and safety of direct-acting oral anticoagulants in patients with non-valvular atrial fibrillation: a meta-analysis // Europace. 2020. Vol. 22 (3). P. 361–367. DOI: 10.1093/europace/euz361. PMID: 31985781.
  12. Lee C.H., Lin T.Y., Chang S.H., Chen C.H., Hsu Y.J., Hung K.C. et al. Body mass index is an independent predictor of major bleeding in non-valvular atrial fibrillation patients taking dabigatran // Int. J. Cardiol. 2017. Vol. 228. P. 771–778. DOI: 10.1016/j.ijcard.2016.11.277.
  13. Lee S.R., Choi E.K., Park C.S., Han K.D., Jung J.H., Oh S. et al. Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight // J. Am. Coll. Cardiol. 2019. Vol. 73 (8). P. 919–931. DOI: 10.1016/j.jacc.2018.11.051.
  14. Deng Y., Tong Y., Deng Y., Zou L., Li S., Chen H. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis // J. Am Heart Assoc. 2019. Vol. 8 (14). P. e012540. DOI: 10.1161/JAHA.119.012540.
  15. Ording A.G., Horváth-Puhó E., Adelborg K., Pedersen L., Prandoni P., Sørensen H.T. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study // Cancer Med. 2017. Vol. 6 (6). P. 1165–1172. DOI: 10.1002/cam4.1054.
  16. Sulzgruber P., Wassmann S., Semb A.G., Doehner W., Widimsky P., Gremmel T. et al. Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 // Eur. Heart J. 2019. Vol. 40 (36). P. 3010–3012. DOI: 10.1093/eurheartj/ehz650. PMID: 31541549.
  17. Steffel J., Verhamme P., Potpara T.S., Albaladejo P., Antz M., Desteghe L. et al. ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation // Eur. Heart J. 2018. Vol. 39(16). P. 1330–1393. DOI: 10.1093/eurheartj/ehy136.

Для продолжения работы требуется вход / регистрация